STOCK TITAN

Longeveron Executive Gets $187K Stock Grant as Compensation Package

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Longeveron General Counsel and Secretary Paul T. Lehr reported significant insider transactions on June 23, 2025. The transactions involved:

  • Acquisition of 163,043 restricted stock units (RSUs) that fully vested on the grant date
  • Disposition of 64,158 shares at $1.15 per share through share withholding for tax obligations
  • Following these transactions, Lehr holds 255,635 shares directly, including RSUs subject to future vesting

The Form 4 filing demonstrates substantial equity-based compensation for a key executive officer, with immediate vesting of the new RSU grant. The share withholding for tax purposes is a common practice for executive equity compensation arrangements. This insider activity provides insights into Longeveron's executive compensation structure and retention strategies.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lehr Paul T

(Last) (First) (Middle)
1951 NW 7TH AVENUE
SUITE 520

(Street)
MIAMI FL 33136

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Longeveron Inc. [ LGVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel, Secretary
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/23/2025 A 163,043(1) A $0 319,793 D
Class A Common Stock 06/23/2025 F 64,158(2) D $1.15 255,635(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an award of restricted stock units (RSUs), which fully and completely vested on the grant date of June 23, 2025.
2. Shares withheld to satisfy the tax obligations in connection with the vesting of an RSU award.
3. Includes RSUs subject to future vesting.
Remarks:
/s/ Paul T. Lehr 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many LGVN shares did General Counsel Paul Lehr receive in RSUs on June 23, 2025?

Paul Lehr received 163,043 restricted stock units (RSUs) on June 23, 2025, which fully vested on the grant date.

What was the price of LGVN shares withheld for tax purposes in Lehr's June 2025 transaction?

64,158 LGVN shares were withheld at a price of $1.15 per share to satisfy tax obligations related to the RSU vesting.

How many LGVN shares does Paul Lehr own after the June 23, 2025 transactions?

After the transactions, Paul Lehr owns 255,635 shares of LGVN Class A Common Stock, which includes RSUs subject to future vesting.

What position does Paul Lehr hold at LGVN according to the Form 4?

Paul Lehr serves as General Counsel and Secretary of Longeveron Inc. (LGVN).

What type of insider transaction did LGVN's General Counsel report in June 2025?

The General Counsel reported receiving an RSU award of 163,043 shares that vested immediately, with 64,158 shares being withheld for tax obligations, resulting in a net acquisition of LGVN shares.
Longeveron Inc

NASDAQ:LGVN

LGVN Rankings

LGVN Latest News

LGVN Latest SEC Filings

LGVN Stock Data

10.90M
16.90M
14.83%
6.96%
5.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI